AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Other Eye Care by Quarter
Other Eye Care — International reported growth YoY (%) (%)
AbbVie Other Eye Care: -1.5% in Q4 2025, down 16.9 pts from a year earlier.
Latest, Q4 2025
-1.5%
Period ended Dec 31, 2025
Change on a year earlier
-16.9 pts
15.4% in Q4 2024
History
18 quarters
Since Q3 2021
Sources
18
Documents cited below
Where the Q4 2025 figure comes from
“|| Other Eye Care | 189 | 105 | 294 | (14.9) | (1.5) | (10.5) | (2.3) | (10.8)”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Key Product Revenues Schedule.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Other Eye Care (%), quarterly Q3 2021–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/other-eye-intl-rep-yoy
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.